

Caso Clínico

Case Report

A Murinello¹
H Damásio²
AM Figueiredo³
J Netta⁴
A Carvalho⁵
AA Matos⁶
MJ Murillo⁷
A Albuquerque⁸

Estômago em melancia, pericardite hemorrágica, tumor de pequenas células do pulmão e carcinoma pavimentocelular síncrono da base da língua

Watermelon stomach, hemorrhagic pericarditis, small cell carcinoma of the lung and synchronous squamous cell carcinoma of the tongue base

Recebido para publicação/received for publication: 09.05.21
Aceite para publicação/accepted for publication: 10.01.07

Resumo

Baseados num caso de gastropatia antral com ectasia vascular (estômago em melancia) associado a pericardite hemorrágica e a um carcinoma de pequenas células do pulmão com metástases ganglionares ao longo do mediastino e a um carcinoma pavimentocelular síncrono da base da língua, os autores fazem uma revisão dos aspectos clínicos, endoscópicos e histopatológicos deste tipo de gastropatia, da sua associação a outras doenças e das possibilidades terapêuticas actuais por via endoscópica. Referem-se igualmente as causas mais frequentes de pericardite hemorrágica, salientando-se a

Abstract

Based on a case of gastric antral vascular ectasia (watermelon stomach) that was associated with hemorrhagic pericarditis, small cell lung carcinoma with mediastinal lymph node metastases and a synchronous squamous cell carcinoma of the base of the tongue, the authors made a review of the clinical, endoscopic and histopathological aspects of this type of gastropathy, and its association with other diseases, and of the results of its endoscopic therapy. The causes of hemorrhagic pericarditis are considered, emphasizing the necessity to know if the effusion has

¹ Graduated Chief Service of Internal Medicine of the HCL (Hospital Curry Cabral)

² Graduated Hospital Assistant of Internal Medicine (Medicine 1)

³ Resident of Internal Medicine (Medicine 1)

⁴ Resident of Histopathology

⁵ Graduated Hospital Assistant of Histopathology

⁶ Biologist, Ph.D. Superior Technician of Health. Histopathology (Electron Microscopy)

⁷ Hospital Assistant of Histopathology

⁸ Resident of the Common Year

Units: Internal Medicine 1, Histopathology
Hospital Curry Cabral. Lisboa. Portugal
e-mail: amurinello@yahoo.com

necessidade de esclarecer se o derrame é ou não de origem neoplásica. Não está referida na literatura a associação deste tipo de gastropatia ao carcinoma de pequenas células do pulmão nem ao carcinoma pavimento-celular da base da língua. A invasão extensa dos gânglios mediastínicos pelo carcinoma de pequenas células do pulmão é ocorrência frequente.

Rev Port Pneumol 2010; XVI (4): 659-670

Palavras-chave: Gastropatia antral com ectasia vascular, estômago em melancia, carcinoma de pequenas células do pulmão, carcinoma pavimento-celular da base da língua, pericardite hemorrágica.

a malignant etiology. To the best of our knowledge the association of watermelon stomach to small cell lung carcinoma and squamous cell carcinoma of the base of the tongue has not yet been described. Extensive metastases to mediastinal lymph nodes are common to small cell lung carcinoma.

Rev Port Pneumol 2010; XVI (4): 659-670

Key-words: Gastric antral vascular ectasia, watermelon stomach, small cell lung carcinoma, oat cell lung carcinoma, squamous cell carcinoma of the base of the tongue, hemorrhagic pericarditis.

Introduction

Watermelon stomach is a characteristic endoscopic finding of Gastric Antral Vascular Ectasia (GAVE), so named because of the intensely erythematous longitudinal streaks or columns of ectatic and sacculated blood vessels at the apices of prominent folds running across the gastric antrum and radiating to the pylorus sphincter, and resembling strips on a watermelon rind^{1,2}. GAVE is different from ordinary antral gastritis by its location on the antral folds and sharply demarcated lesion that blanches on pressure³.

GAVE is a rare cause of chronic iron deficiency anaemia due to slow and intermittent gastrointestinal bleeding, brought about by the erosion of submucosal ectatic vessels through the gastric mucosa⁴. Since the diagnosis is often delayed, it is common for patients to have received multiple packed red cell transfusions⁵. Even though it is a

rare disorder, GAVE is responsible for roughly 4% of non-variceal upper gastrointestinal bleeding⁶. Profuse gastric hemorrhage is rare with this disorder but may occur as a result of superimposed bleeding diathesis which is present in the majority of patients reporting melena, and is determined by the concomitant presence of conditions such as biliary cirrhosis, valvular heart disease, congestive heart failure, non-steroidal anti-inflammatory use, CREST syndrome and systemic sclerosis, and chronic renal insufficiency, which can occur in association with watermelon stomach³. Most cases of GAVE are idiopathic and occur more commonly in older women (with a 9:1 female-to-male ratio). Achlorhydria is a frequent finding in these patients due to atrophic gastritis⁷. Rarely, GAVE may occur in association with bone marrow transplantation⁸, pernicious anemia⁹, diabetes¹⁰, chronic obstructive pulmonary disease¹⁰,

lymphoma¹¹, glucagonoma¹², and neuroendocrine tumor (gastric carcinoid)¹⁰.

The association of GAVE with cirrhosis and portal hypertension is considered unreliable with regards to a cause and effect relationship¹³. It is important to differentiate GAVE from portal gastropathy because the former responds to endoscopic therapy but not to portal hypertension reduction, whereas the latter does not respond to endoscopic therapy but responds to portal pressure reduction¹³.

The authors present a case of a 59-year-old woman with a previous history of chronic anemia, who was admitted due to acute dyspnea and with an initial diagnosis of hypoxemic bronchopneumonia. The investigation of the patient concludes for the association of GAVE to: (1) Small Cell Lung Carcinoma (SCLC) with mediastinal lymph node metastases, (2) a synchronous Squamous Cell Carcinoma of the base of the tongue, and (3) malignant hemorrhagic pericarditis.

Clinical report

A 59-year-old Caucasian female was admitted to our Unit on 08AUG21 due to progressive dyspnea with a provisory diagnoses of Acute Bronchopneumonia, Congestive Heart Failure and Iron Deficiency Anemia. She was started on Ceftriaxone and Chlarytromycin.

The patient started feeling sick a month prior to admission (PTA), when she became anorexic and asthenic. Fifteen days PTA, the patient developed cough productive of mucopurulent sputum. Ten days PTA, she began to complain of odynophagia and dysphagia for solid food, as well as progressive orthopnea. There was also associated 10 kg weight loss. She denied any other symp-

toms. Past medical history revealed she had been treated for pulmonary tuberculosis (20 years ago) and gastric ulcer. She was also frequently noted to be anemic. She has been a heavy smoker (40 cigarettes/day) and a heavy alcoholic drinker (but has stopped 12 years ago).

On **physical exam** she was pale, very thin, profoundly dehydrated, and in respiratory distress with a RR=30 breaths/min, BP=87/68 mm Hg, HR=97 beats/min, T^o=35.5°C. and supraclavicular retraction, blood pressure 87/68 mm Hg, heart rate 97 bpm, temperature 35.5°C. She was edentulous and had frequent sialorrhoea. There was supraclavicular retraction and numerous supraclavicular lymphadenopathies. Thyroid gland was unenlarged. Auscultation of the lungs revealed bilateral diffuse ronchi and wheezes. Heart sounds were slightly muffled. Negative for breast masses, hepatosplenomegaly and peripheral edema.

Blood tests showed the following findings: leukocytosis with neutrophilia (18 600/mm³; 94.3%); microcytic anemia (Hb 7.5 g/dL; MCV 76.4 fl; MCH 24.2 pg), adequate platelets. Normal protime, elevated PCR 16.4 mg/dL (N<1.00); hypoalbuminemia 2.62 g/dL; low serum iron and transferrin and ferritin; no monoclonal gammopathy; elevated LDH 752 U/L (N 313-618); other biochemical analysis were normal (glucose; renal and liver function tests; lipid profile; calcium and phosphorus); normal thyroid function tests; Arterial Blood Gas: respiratory alkalosis and hypoxemia (pH 7.514; pCO₂ – 32.7 mmHg; pO₂ – 53.1 mmHg; HCO₃⁻ mmol/L; Sat O₂ – 90.2%); several **blood cultures**, including BACTEC, were negative. **Sputum exam**: Ziehl-Nielsen and Lowenstein were negative. The **Chest**

PA revealed an enlarged cardiac silhouette, a widened superior mediastinum and an ill-defined image of right paracardiac condensation (Fig. 1A). A comparative reading with a chest x-ray dated Dec 2006 (Fig. 1B) lead us to suspect pericardium effusion, which was confirmed by **echocardiography**, showing massive effusion and signs of cardiac pre-tamponade, with diastolic collapse of the right atria and pre-collapse of the right ventricle (Fig. 1C), and estimated PSAP of 51 mm Hg. An immediate **pericardiocentesis** was performed with drainage of 820 mL of pericardial hemorrhagic effusion (in two days) that yielded moderately elevated number of granulocytes and erythrocytes, but negative for *Mycobacteria* and other bacteria on culture. No malignant cells found. **Upper gastrointestinal endoscopy to explain dysphagia** showed a normal esophagus, but revealed typical aspects of GAVE (Fig. 2). We were unable to confirm it histologically through biopsy, because the patient became very dyspneic during the procedure. Bronchofibroscopy was not possible to realize due to progressive respiratory failure and the impossibility to do it in our hospital. **Biopsy of a supraclavicular lymph node** showed infiltration by small cell carcinoma (CAM 5.2 +, AE1/AE3 +, CK7 +; sinaptophysin +, LCA -, TTF1 -, cromogranin -; S100 -). The patient's condition rapidly deteriorated with development of acute pulmonary edema. After stabilizing the patient, a **non-contrast thoracic CT scan** (Fig. 3) was done, which revealed prominence of the central pulmonary artery and main right and left branches; numerous hypertrophied mediastinal lymphadenopathies, mainly in the peri-esophageal area, causing compression of the medium esophagus and also of the main right



Fig. 1 – A/B: PA views of the thorax X-rays (AUG08/DEC06) revealing significant enlarged cardiac silhouette; C: Echocardiography: cardiac pre-tamponade due to voluminous anterior and posterior pericardial effusion




Fig. 2 – Upper gastrointestinal endoscopy showing characteristic aspects of watermelon stomach




Fig. 3 – Thoracic CT-scan: numerous mediastinic lymphadenopathies causing compression of the medial esophagus and of the main right bronchus

and left bronchus. At the level of right middle lobe and of the lingual lobe there were images suggestive of infection. The patient died on the 7th hospital day (08AUG28) due to respiratory failure. There were no medical conditions to proceed to bronchofibroscopy. **Necropsy** revealed the following **macroscopic** and **microscopic** (hematoxylin-eosin) aspects (Figs. 4 A,B,C; 5 A,B,C; 6

A,B,C; 7 A,B,C): **Macroscopically**: a) an ulcerated tumor of the base of the tongue measuring 3.5 cm at its widest diameter; b) a mediastinal tumor mass comprising a lymphadenopathic conglomerate involving all the compartments and the right pulmonary hilus, the main right bronchus and a small adjacent area of the lung; c) a tumor metastasis on the right adrenal; d) a tumor metastasis on the right kidney; e) a tumor metastasis on the spleen; **Microscopically**: a small cell carcinoma (identical to the one described on the ganglionic biopsy) of the right bronchus with extensive mediastinal, tracheal and ganglionic extension, and with metastasis to the spleen, right adrenal, right kidney, pericardium, and hypophysis. Small cell carcinoma was confirmed by neuroendocrine markers using immunohistochemis-




Fig. 4 – A: Base of the tongue with an extensive ulcerated lesion, with macroscopic extension to the valecula; B: HE 10X5 – Squamous neoplasia (T) infiltrating the muscle of the tongue and the minor salivary glands (G), ulcerating (U) the squamous epithelium (E); C: HE 10X10 – Squamous cell carcinoma (T) proliferating and infiltrating the neighbour tissues, adipose tissue (A), muscle (M).

ESTÔMAGO EM MELANCIA, PERICARDITE HEMORRÁGICA, TUMOR DE PEQUENAS CÉLULAS DO PULMÃO E CARCINOMA PAVIMENTOCELULAR SÍNCRONO DA BASE DA LÍNGUA

A Murinello, H Damásio, AM Figueiredo, J Netta, A Carvalho, AA Matos, MJ Murillo, A Albuquerque




Fig. 5 – A: Right lung with a tumor mass proliferating within the submucosa of the main bronchus and infiltrating the hilus. The mucosal surface of the bronchial tree was intact; B: HE 10X10 – SCLC with necrosis (N); C: HE 10X10 – Lymphatic invasion by the SCLC (A)






Fig. 7 – A: HE 10X10 – Spleen metastasis of SCLC; B: HE 10X10 – Hypophysis gland metastasis of SCLC and squamous cell carcinoma; C: HE 10X10 – Pericardium metastasis of SCLC





Fig. 6 – A: Macroscopic aspect of adrenal gland metastasis; B: HE 10X10 – Adrenal gland metastasis of SCLC; C : HE 10X10 – Kidney metastasis of SCLC, with lymphatic invasion (I)




Fig. 8 – Immunohistochemistry: A: 10X40 – SCLC expressing neuroendocrine markers (chromogranin, NSE, and synaptophysin); B: 10X40 – The neoplasia that involved the hypopharynx, expressed positivity for cytokeratins (34BE12 or CK903)

try (Fig. 8A). Surprisingly, the tumor located at the tongue base was a (synchronous) squamous cell carcinoma with metastasis only in the hypopharynx, which was confirmed by immunohistochemistry (Fig. 8B). There were areas with poorly differentiated pattern but the neuroendocrine markers (synaptophysin, chromogranin, NSE) were consistently negative. The ultrastructural study performed on both tumors (bronchus and tongue) by electron microscopy confirmed the aforementioned different nature of these tumors (Fig. 9).

Discussion

The findings of a prominent antral folds and antral thickening in upper gastrointestinal radiologic series and on CT scans in an elderly patient with chronic anemia should alert the radiologist to the possibility of GAVE, which should be confirmed endoscopically with biopsy¹⁴.

GAVE can be safely biopsied with only minimally increased and minor bleeding because of its low-intravascular pressure. Biopsy of the involved gastric folds reveals

characteristic findings of dilated, tortuous mucosal capillaries often occluded by bland fibrin thrombi in the lamina propria and dilated submucosal veins without inflammatory infiltration^{15,16}, together with foveolar




Fig. 9 – Post-mortem samples recovered from paraffin blocks and reprocessed for electron microscopy: A: Tumor of the base of the tongue. The cytoplasm of the tumor cells displays well developed bundles of keratin filaments (Q). Inset – High magnification of keratin filament; B: Mediastinic tumor. Dense neurosecretory-like granules (arrows) in the cytoplasm of the tumor cells

hyperplasia and fibromuscular spindle cell hyperplasia of the lamina propria¹⁷.

The cause of GAVE is unknown, but Jabbari¹ had proposed that it could result from repetitive low-grade trauma caused by repeated prolapse of the loosely attached mucosa of the distal antrum into the duodenum during gastric peristalsis due to antral hypercontractility, primary or acquired, with consequent elongation and secondary reactive muscular hyperplasia and ectasia of the mucosal vessels. Thrombosed ectatic vessels are a distinctive feature and are seen only in GAVE^{18,19}.

Since GAVE is not acid related pharmacotherapy with histamine receptor antagonists and proton pump inhibitors is ineffective. Evidence for effective pharmacologic therapy with oestrogen (and/or progesterone), tranexamic acid or thalidomide, are mentioned in some case reports only⁶. Ultimately, treatment of any underlying medical comorbidities may lead to resolution of GAVE⁶. Many authors consider endoscopic therapy as the primary therapy, namely argon plasma coagulation (APC), which appears to be preferable in comparison with contact methods (heater probe, electrocautery with bipolar electrocoagulation probe, or Gold probe) or other noncontact ablative modality (Nd:YAG laser). Despite some contrary opinion¹⁰, APC should probably be the treatment of choice for GAVE due to the diffuse nature and superficial location of the lesion^{20,21}. APC is well tolerated and safe because it produces only shallow tissue injury²². Usually several sessions are needed, but requirements of blood transfusions are generally diminished in the large majority of patients^{23,24,25}.

Antrectomy is recommended if endoscopic hemostasis fails. It removes the lesion and

nearly always cures the disease, but entails significant morbidity and 5% mortality²⁶.

Despite the generally good results obtained with APC, recently there were some authors who were able to get a much better result with Endoscopic Band Ligation (EBL) in cases of GAVE (especially in patients having large areas of diseased mucosa and submucosa)²⁷ that have been treated with APC but would still have recurrent hemorrhage²⁷. These authors suggest that EBL could be more superior to endoscopic thermal therapy (ETT) for the management of GAVE. In their study consisting of 22 patients treated either with EBL or ETT, including four patients in the EBL group that failed prior ETT, they found that statistically EBL had a significantly higher rate of bleeding cessation (67% vs 23%, $P = .04$), fewer treatment sessions required for cessation of bleeding (1.9 vs 4.7, $P = .05$), a greater increase in hemoglobin values (2.8 g/dL vs 0.9 g/dL, $P = .05$), a greater decrease in transfusion requirements (-12.7 vs -5.2, $P = .02$), and a greater decrease in hospital admissions (-2.6 vs -0.5, $P = .02$) during the follow-up period. EBL for GAVE includes ligation bands applied to abnormal-appearing mucosa in the antrum, beginning in the most distal antrum, adjacent to the pylorus, and subsequently more proximally until as much as possible of the abnormal-appearing mucosa, thus obtaining resection of large amounts of antral mucosa and submucosa. The superiority of EBL compared with ETT is probably due to the fact that EBL providing more reliable obliteration of the abnormal vasculature in the mucosa and submucosa. Complications are also rarer with EBL than with APC²⁷.

The main causes of non-traumatic hemorrhagic pericarditis are tuberculosis in deve-

loping countries, frequently associated today with AIDS²⁸, and malignancy in developed²⁹. Meyers *et al*³⁰ demonstrated that most pericardial effusions are sero-sanguineous or hemorrhagic (72.6%), there was a great number of possible etiologies, and erythrocytes counts were not significantly different among the diagnostic groups. Other possible causes are post-myocardial infarction rupture of the free wall of the ventricle, retrograde bleeding due to dissecting aneurysm of the proximal thoracic aorta (mostly due to atherosclerotic disease; on old times also syphilitic aneurysm), anticoagulant or antifibrinolytic therapy, congestive heart failure, uremia, connective tissue diseases, and any type of infectious pericarditis^{31,32,33,34,35,36,37,38,39}.

In a review of 127 patients with malignancy-related pericardial effusion by Wilkes⁴⁰, 55% of cases were malignant in etiology while in the remaining 45%, a malignant cause for the effusion could not be determined and no definitive etiology was identified in 74% of these effusions. Diagnosis by cytology and pericardial biopsy had sensitivities of 90% and 50%, respectively. 71% of primary tumors were adenocarcinomas of the lung, breast, esophagus, hematologic malignancies, and of unknown primary site.

Effusions caused by tumors often progress to cardiac tamponade, eliciting bleeding in the pericardium^{41,42}. Malignancy-related hemorrhagic pericardial effusions are frequently a terminal event in patients with disease unresponsive to therapy. However, bloody pericardial effusion can be the presenting manifestation of a newly diagnosed malignancy, either metastatic^{43,44,45,46,47}, or rarely due to primary malignancy of the

pericardium (ex^o mesothelioma⁴⁸). We shall also think on the possibility of pericardial effusion due to primary malignancy of the heart, and on Kaposi sarcoma and lymphoma in patients with AIDS⁴⁸.

In most cancer patients with pericardial effusion, or tamponade, it is important that neoplastic involvement of the pericardium be confirmed by identification of malignant cells in pericardial fluid. Confirmation is important because other forms of pericardial disease can occur in patients who have or had cancer^{48,49,50}.

In our patient the cytological examination of the pericardium fluid was negative, but the extensive histological analysis of the pericardium during necropsy, revealed a tiny metastatic focus of small cell carcinoma, confirming the clinical suspicion of a malignant etiology of the pericardium effusion.

The median age at diagnosis for primary cancer of the tongue is 61 years of age. The lifetime risk of developing cancer of the tongue is 1 in 361 men and woman⁵¹. People who drink large amounts of alcohol and use tobacco are especially at risk. Tongue cancers are subdivided in cancers of the proximal two-thirds of the tongue – buccal tumors, and cancers of the posterior third – tongue base cancers or oropharyngeal cancers, which are often diagnosed quite late. Most of the tumors are squamous cells tumors⁵².

Symptoms of cancer of the tongue are: (a) chronic pain in the pharynx, mostly at mastication or swallowing, (b) numbness of the tongue or of the mouth, (c) a small lump, (d) unexplained bleeding from the tongue⁵³, (e) non-cicatrizing ulcer of the tongue, (f) otalgia due to pain irradiation, (g) bad breath, (h) drooling, (i) difficulty in breath-

ing, (j) trouble swallowing, (k) difficulty in speaking, (l) bad odour breath. If untreated, the tumor may spread throughout the tongue to the floor of the mouth and to the gum (jaws). As tumor grows it can evolve to cause metastases to lymph nodes in the neck and later on in the rest of the body⁵⁴.

Neuroendocrine carcinomas are tumors and are more commonly found in the thyroid, lung and skin. Their diagnosis is based on the recognition of the characteristic morphology and architecture, but immunohistochemical confirmation of the neuroendocrine nature of neoplasm cells is always required.

In our patient, the problem wasn't centered on the histological diagnosis but rather at his origin. The main tumor mass was located at the mediastinum, but is starting to invade the bronchus and lung. We could speculate a thymus origin, but small cell carcinoma is rare at the thymus, and it is much more frequent at the lung. In order to make a diagnosis of small cell carcinoma of the thymus, it is necessary to exclude a lung origin, which we certainly can't do in our case. So, we think that we have to consider that in this patient, the origin was pulmonary with extensive mediastinal and ganglionic extension.

SCLC has an aggressive behavior, with rapid growth, early spread to distant sites (mediastinal lymph nodes, liver, bones, adrenal glands, and brain), frequently exhibit para-neoplasm syndromes and neurologic autoimmune phenomena, and distinct sensitivity to chemotherapy and radiotherapy. Surgery is rarely useful. SCLC generally presents with onset of symptoms within 8-12 weeks prior to admission. The symptoms can result from local tumor growth, intrathoracic

spread, distant spread, para-neoplasm syndromes (inappropriate secretion of antidiuretic hormone, ectopic secretion of ACTH) and autoimmune neurologic phenomena. Common symptoms are fatigue, anorexia, weight loss, cough, dyspnea, hemoptysis, symptoms due to vena cava obstruction, hoarseness, dysphagia, stridor, neurological dysfunction, bone pain, abdominal pain due to metastases. Usually SCLC is centrally located and may cause obstruction of the major airway, with distal collapse and post-obstructive pneumonitis. Due to rapid growth and spread, patients at presentation may have a very large intra-thoracic tumor, making difficult to distinguish primary tumor from lymph node metastases. Pleural and pericardial effusions are common⁵⁵.

Acknowledgments

Due to the following performances at our Hospital: Dr Pratas J (Unit of Gastroenterology) – upper gastrointestinal endoscopy; Drs Brizida L and Dr Ramos A^a (Unit of Cardiology) – cardiac echocardiography and pericardicentesis; Dr Ramalho V (Unit of Radiology) – CT-scan of the thorax

Bibliography

1. Jabbari M, Cherry R, Lough JO, Daly DS, Kinnear DG, Goresky CA. Gastric antral vascular ectasia: the watermelon stomach. *Gastroenterol* 1984; 87:1165-1170.
2. Ikeda M, Ishida H, Nakamura E, *et al.* An endoscopy follow-up study of the development of diffuse antral vascular ectasia. *Endoscopy* 1996; 28:390-393.
3. Novitsky YW, Kercher KW, Czerniach DR, *et al.* Watermelon stomach: pathophysiology, diagnosis and management. *J Gastroint Surg* 2003; 7:652-661.
4. Chatterjee MD. Watermelon stomach. *CMAJ* 2008; 179:162.

ESTÔMAGO EM MELANCIA, PERICARDITE HEMORRÁGICA, TUMOR DE PEQUENAS CÉLULAS DO PULMÃO E CARCINOMA PAVIMENTOCELULAR SÍNCRONO DA BASE DA LÍNGUA

A Murinello, H Damásio, AM Figueiredo, J Netta, A Carvalho, AA Matos, MJ Murillo, A Albuquerque

5. Toyota M, Hiroda Y, Nakogawa N. Gastric antral vascular ectasia causing severe anemia. *J Gastroenterol* 1996; 31:710-713.
6. Selinger CP, Ang YS. Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. *Digestion* 2008; 77:131-137.
7. Bersch G. Diffuse gastric antral vascular ectasia: the "watermelon stomach" revisited (letter). *Am J Gastroenterol* 1987; 82:1333-1334.
8. Herman BE, Vargo JJ, Baum S, Silverman ED, Eisold J. Gastric antral vascular ectasia: a case report and review of the literature. *J Nucl Med* 1996; 37:854-856.
9. Gostout CJ, Viggiano TR, Ahlquist DA, Wang KK, Larson MV, Balm R. The clinical and endoscopic spectrum of the watermelon stomach. *J Clin Gastroenterol* 1992; 15:256-263.
10. Chaves DM, Sakai P, Oliveira CV, Cheng S, Ishiaka S. Watermelon stomach: clinical aspects and treatment with argon plasma coagulation. *Arq Gastroenterol* 2006; 43:191-195.
11. Park RH, Danesh BJ, Upadhyay R, Howatson AG, Lec FD, Russel RJ. Gastric antral vascular ectasia (watermelon stomach) – therapeutic options. *Postgrad Med J* 1990; 66:720-723.
12. Weitgasser R, Sungler P, Hauser-Kroberger C, Dietze O, Sattlegger P, Hacker GW. Immunohistochemical assessment of an asymptomatic glucagonoma in a patient with hypergastrinemia and marked antral angiodysplasia. *Appl Immunohistochem Molecul Morphol* 2001; 9:92-96.
13. Spahr L, Villeneuve JP, Dufresne MP, *et al.* Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. *GUT* 1999; 44:739-742.
14. Urban BA, Jones B, Fisman EK, Kern SE, Ravich WJ. Gastric antral vascular ectasia ("the watermelon stomach"): radiologic findings. *Radiology* 1991; 178:517-518.
15. Gilliam JH 3rd, Geisinger KR, Wu WC, *et al.* Endoscopic biopsy is diagnostic in gastric vascular ectasia: the "watermelon" stomach. *Dig Dis Sci* 1989; 34:885-888.
16. Cappel MS, Fredal D. Acute nonvariceal upper gastrointestinal bleeding: endoscopic diagnosis and therapy. *Med Clin N Am* 2008; 92:511-550.
17. Suit PF, Petras RE, Bauer TW, Petrini JL. Gastric antral vascular ectasia: a histologic and morphometric study of the watermelon stomach. *Am J Surg Pathol* 1987; 11:750-775.
18. DuBouly C, Fairboth J, Isaacson PG. Mucosal prolapse syndrome: a unifying concept for solitary syndrome and related disorders. *J Clin Pathol* 1983; 36:1264-1268.
19. Tuibia N, Sanyal A. Portal hypertension and variceal hemorrhage. *Med Clin N Am* 2008; 92:551-574.
20. Pavey DA, Cray PI. Endoscopic therapy for upper GI vascular ectasia. *Gastroint Endosc* 2004; 59:233-231.
21. Ng I, Lai KC, Ng M. Clinical and histologic features of gastric vascular ectasia: successful treatment with endoscopic laser therapy. *J Gastroent Hepatol* 1996; 11:270-274.
22. Kwan v, Bourke MJ, Williams SJ, *et al.* Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with long-term follow-up. *Am J Gastroenterol* 2006; 101:58-63.
23. Roman S, Saurin JC, Dumortier J, *et al.* Tolerance and efficacy of argon plasma coagulation for controlling bleeding in patients with typical and atypical manifestations of watermelon stomach. *Endoscopy* 2003; 35:1024-1028.
24. Sebastian S, Mehoughin R, Gasim A, *et al.* Endoscopic argon plasma coagulation for the treatment of gastric antral vascular ectasia (watermelon stomach): long-term results. *Dig Liv Dis* 2004; 36:212-217.
25. Pereira-Lima JC, Hornos AP, Marques DL, Lopes CV, Waechter FL, Saul C, *et al.* Tratamento da ectasia vascular do antro gástrico por electrocoagulação com argônio. *GED* 2002, 21:213-217 (in portuguese).
26. Bourke M, Hope DL, Boyd P, *et al.* Endoscopic laser therapy for watermelon stomach. *J Gastroenterol Hepatol* 1996; 11:832-836.
27. Wells CD, Harrison ME, Gurudu SR, Crowell MD, Bynne TJ, Depekis G, *et al.* Treatment of gastric antral vascular ectasia (watermelon stomach) with endoscopic band ligation. *Gastrointest Endosc* 2008; 66:231-236.
28. Mayosi BM, Burgess LJ, Douhell AF. Tuberculous pericarditis. *Circulation* 2005; 112:3608-3616.
29. Dequanter D, Lothaire PH, Berghmans T, Scubier JP. Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. *Ann Surg Oncol* 2008; 15:3268-3271.
30. Meyers DG, Meyers RE, Prendergast TW. The usefulness of diagnostic tests on pericardial fluid. *Chest* 1997; 111:1213-1221.

ESTÔMAGO EM MELANCIA, PERICARDITE HEMORRÁGICA, TUMOR DE PEQUENAS CÉLULAS DO PULMÃO E CARCINOMA PAVIMENTOCELULAR SÍNCRONO DA BASE DA LÍNGUA

A Murinello, H Damásio, AM Figueiredo, J Netta, A Carvalho, AA Matos, MJ Murillo, A Albuquerque

31. Hoit BD. Pericardial disease and pericardial tamponade. *Crit Care Med* 2007; 35:8(Suppl.)S355-S364.
32. Stern JB, Sobel HJ. Hemorrhagic rheumatoid pericarditis. *Am J Cardiol* 1961; 8: 670-673.
33. Saxena A, Singh N, Romakrishnan S, Kothari S. Bacterial pericarditis presenting as hemorrhagic pericardial effusion in a 6-year-old girl. *Ann Pediatr Card* 2008; 1:68-69.
34. Tenenbaum T, Heusch A, Henrich B, Mackenzie CR, Schmidt KG, Schrotten H. Acute hemorrhagic pericarditis in a child with pneumonia due to *Chlamydo-philum pneumoniae*. *J Clin Microbiol* 2005; 43:520-522.
35. Zanini G, Antonioli E, Vizzardi E, Raddino R, Cas LD. Hemorrhagic pericarditis with cardiac tamponade due to Coxsackie virus infection. *Am J Clin Reports* 2008; 9:60-63.
36. Spodick DH. Infectious pericarditis. In Spodick DH (Ed.). *The pericardium: a comprehensive textbook*. New York: Marcel Dekker 1997: 260-290.
37. Zayas R, Anguit M. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. *Am J Cardiol* 1995; 75:378-382.
38. Permaneyer-Miralda G. Acute pericardial disease: approach to the etiologic diagnosis. *Heart* 2004; 90:252-254.
39. Olson LJ, Edwards WD, Olney BA, Orsulak TA, Josa M. Hemorrhagic cardiac tamponade: a clinicopathologic correlation. *Mayo Clin Proc* 1984; 59:785-790.
40. Wilkes JD, Fidias P, Vaickus L, Perez RP. Malignancy-related pericardial effusion: 127 cases from the Roswell Park cancer Institute. *Cancer* 1995; 76:1377-1387.
41. Valley VT, Fly CA. Pericarditis and cardiac tamponade. Available at: <http://www.emedicine.com/EMERG/topic412.htm> – Updated May 12, 2008.
42. Spodick DH. Acute pericarditis, pericardial effusion and cardiac tamponade. *Bull Saudy Heart Association* 1990; 2:67-76.
43. Atar S, Chiu J, Forrester JS, Siegel RJ. Bloody pericardial effusion in patients with cardiac tamponade – Is the cause cancerous, tuberculous, or iatrogenic in the 1990's? *Chest* 1999; 116:1564-1569.
44. Tsolakis EJ, Charitos CE, Mitsibounas D, Nanas JN. Cardiac tamponade rapidly evolving toward constrictive pericarditis and shock as first manifestation of noncardiac cancer. *J Cardiac Surg* 2004; 19:134-135.
45. Muir KW, Rodger JC. Cardiac tamponade as the initial manifestation of malignancy: is it as rare as previously supposed? *Postgraduate Med J* 1994; 70:703-707.
46. Fincher RM. Case report: malignant pericardial effusion as the initial manifestation of malignancy. *Am J Med Sci* 1993; 305:106-110.
47. Yuan P-J, Wong W-K. Cardiac tamponade as the initial presentation of thymic carcinoma – A case report. *Acta Cardiol Sin* 2006; 22:112-116.
48. Lewinter MM, Kabbani S. Pericardial diseases. In Zippes DP, Libby P, Bonow RO, Braunwald E (Eds.). *Braunwald's heart disease 7th ed.* Philadelphia: Elsevier Saunders 2005: 1757-1780.
49. Ben-Horin S, Bank I, Guetta V, Livneh A. Large symptomatic pericardial effusion as the presentation of unrecognized cancer: a study in 173 consecutive patients undergoing pericardiocentesis. *Medicine* 2006; 85:49-53.
50. Chiles C, Woodard RD, Singh SP, Lipy GY. Management of pericardial effusion by drainage: a survey of 10 years experience in a city centre general hospital serving a multiracial population. *Postgraduate Med J* 2000; 76:809-813.
51. Edwards BK (Eds.). *SEER cancer statistic reviews, 1997-2005*, National Cancer Institute. Bethesda. Available at: http://seer.cancer.gov/csr/1975_2005/.
52. Available at: <http://www.mayoclinic.org/tongue-base-cancer/> Tongue base cancer – Diagnosis and treatment options at Mayo Clinic.
53. Marioni G, Savartano M, Mattioli L, Koussis H, Carpena S, Marina F, *et al.* Tongue base metastasis from neuroendocrine endometrial small cell carcinoma. *Am J Otolaryng* 2007; 28:284-287.
54. Available at: <http://www.cancer-info-guide.com/tongue-cancer.html>.
55. Magfoor I, Perry M. Lung cancer, oat cell (small cell). In Internet GIST Alliance. Available at: <http://emedicine.medscape.com/article/280104>, overview, Updated October 15, 2008.